Practical radiation oncology · 2026
All-in-one radiotherapy for oncologic emergencies using an integrated CT-linac system: a retrospective cohort study of workflow efficiency and clinical outcomes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peng Haibo, Xu Ningyue, Wu Haohong, Luo Xing, Liu Tao, Yang Fang, Li Pengcheng, Gao Dong, Jia Lecheng, Tan Huigang, Zhang Jie, Zhou Yangang, Ren Tao
Аннотация
PURPOSE: To evaluate the workflow efficiency, dosimetric accuracy, and clinical outcomes of an all-in-one (AIO) radiotherapy workflow for oncologic emergencies using an integrated CT-linac system.
METHODS AND MATERIALS: This retrospective study included 155 patients (Jan 2022-Dec 2025). A template-based AIO protocol was pre-established from conventional planning. Evaluation covered dosimetry, efficiency, and clinical response.
RESULTS: All 155 patients received AIO radiotherapy as first treatment. Median prescription target coverage was 95.00% (range, 83.98%-99.98%); 95.48% met clinical goals. Median organ at risk sparing compliance was 100%. Median 2D in-vivo gamma passing rate (GPR) (3%/3 mm) was 97.35% (IQR, 95.20%-98.96%); offline 3D reconstructed GPR (0.01% uncertainty) was 92.26% (IQR, 90.88%-93.80%). Phantom-based GPR (3%/2 mm) was 100% (IQR, 99.87%-100%). Median total workflow time was 24.66 min (IQR, 20.49-31.52). Acute symptom relief occurred in 89.68% of patients. Median ECOG performance status improved from 2 to 1 (P=0.001). In patients with superior vena cava syndrome, median respiratory rate decreased from 24.5 to 20 breaths/min (P=0.001). Median NRS pain score decreased from 3 to 1 (P<0.001). Among bleeding patients, 86.67% had reduced bleeding and 53.33% achieved complete hemostasis. Three-month local control was 96.77%, with mild radiotherapy-related toxicity; median overall survival 5.37 months (95% CI: 4.28-7.01). Cumulative survival rates at 3, 6, 12, 24 months were 63.70%, 45.20%, 29.40%, and 25.10%.
CONCLUSIONS: The template-based AIO radiotherapy workflow enables rapid admission-to-treatment, delivering clinically acceptable plans with high accuracy. It allows rapid relief of acute symptoms and widens the window for subsequent therapy.
METHODS AND MATERIALS: This retrospective study included 155 patients (Jan 2022-Dec 2025). A template-based AIO protocol was pre-established from conventional planning. Evaluation covered dosimetry, efficiency, and clinical response.
RESULTS: All 155 patients received AIO radiotherapy as first treatment. Median prescription target coverage was 95.00% (range, 83.98%-99.98%); 95.48% met clinical goals. Median organ at risk sparing compliance was 100%. Median 2D in-vivo gamma passing rate (GPR) (3%/3 mm) was 97.35% (IQR, 95.20%-98.96%); offline 3D reconstructed GPR (0.01% uncertainty) was 92.26% (IQR, 90.88%-93.80%). Phantom-based GPR (3%/2 mm) was 100% (IQR, 99.87%-100%). Median total workflow time was 24.66 min (IQR, 20.49-31.52). Acute symptom relief occurred in 89.68% of patients. Median ECOG performance status improved from 2 to 1 (P=0.001). In patients with superior vena cava syndrome, median respiratory rate decreased from 24.5 to 20 breaths/min (P=0.001). Median NRS pain score decreased from 3 to 1 (P<0.001). Among bleeding patients, 86.67% had reduced bleeding and 53.33% achieved complete hemostasis. Three-month local control was 96.77%, with mild radiotherapy-related toxicity; median overall survival 5.37 months (95% CI: 4.28-7.01). Cumulative survival rates at 3, 6, 12, 24 months were 63.70%, 45.20%, 29.40%, and 25.10%.
CONCLUSIONS: The template-based AIO radiotherapy workflow enables rapid admission-to-treatment, delivering clinically acceptable plans with high accuracy. It allows rapid relief of acute symptoms and widens the window for subsequent therapy.